AAVs are widespread in the human population, with a significant proportion of individuals showing evidence of prior exposure, as indicated by the presence of antibodies against the virus. However, because AAVs do not cause disease, their prevalence does not have the same public health implications as more pathogenic viruses. Understanding the epidemiology of AAV infections can aid in the design of effective gene therapies, particularly in anticipating and managing immune responses.
